2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
47
Carcinoma, Non-Small-Cell Lung
16
Colorectal Neoplasms
14
Lung Neoplasms
11
Neoplasm Metastasis
10
Pancreatic Neoplasms
9
Brain Neoplasms
9
Neoplasms
8
Triple Negative Breast Neoplasms
6
Skin Neoplasms
5
Colonic Neoplasms
5
Rectal Neoplasms
4
Ovarian Neoplasms
4
Uveal Melanoma
3
Thyroid Neoplasms
3
Multiple Myeloma
3
Hematologic Neoplasms
3
Glioma
3
Gastrointestinal Stromal Tumors
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Solid Tumor
2
Skin Diseases
2
Recurrence
2
Neurofibromatosis 1
2
Lymphoma
2
Leukemia, Hairy Cell
2
Hereditary Sensory and Autonomic Neuropathies
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Interventions
pembrolizumab
5
Oxaliplatin
3
Nivolumab
3
sintilimab
2
Leucovorin
2
Immune Checkpoint Inhibitors
2
Fluorouracil
2
Capecitabine
2
Bevacizumab
2
vicriviroc
1
trifluridine tipiracil drug combination
1
spartalizumab
1
relatlimab
1
regorafenib
1
epacadostat
1
dabrafenib
1
copanlisib
1
binimetinib
1
atezolizumab
1
Tiragolumab
1
Irinotecan
1
Fulvestrant
1
E7046
1
Cetuximab
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Spinocerebellar Degenerations
×
binimetinib
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts